REGENERX BIOPHARMACEUTICALS INC

Regenerx Biopharmaceuticals Inc operates in Pharmaceutical Preparations (SIC 2834) as a developer of targeted therapeutic proteins and delivery systems intended to address chronic vascular and inflammatory conditions; the company blends clinical research with manufacturing know-how to supply hospitals, specialty physicians, and health systems that demand differentiated biologics and supportive services, while also partnering with managed care groups on patient access strategies. CIK 707511 anchors the public reporting, and the November 1999 Form 8-K remains the most recent SEC disclosure, reflecting how the small-cap entity has historically engaged regulators and investors. Core risks stem from the cost and uncertainty of obtaining FDA and other international approvals, the need to maintain strict GMP-compliant production in the face of supply-chain pressures, and the limited commercial footprint that heightens sensitivity to reimbursement shifts; oversight by agencies such as the FDA and DEA shapes every stage from trials to distribution. View live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025